This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses may be missing. Find their university profile.
Research
Latest papers
F2,6BP restores mitochondrial genome integrity in Huntington's disease.
The Journal of biological chemistry · 2026
Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics.
Molecular pharmaceutics · 2026
Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics.
Drug delivery and translational research · 2025
Latest funding
- $1,005,976
Polynucleotide kinase/phosphatase: its role in DNA strand break repair and a potential cancer therapeutic target
CIHR · 2025 · Nominated PI
- $868,275
Nano-carriers of novel inhibitors of DNA repair for enhanced therapy in unresectable lung cancer
CIHR · 2024 · Co-investigator
- $654,075
Targeted delivery of novel inhibitors of DNA repair and combination treatments for the modulation of therapeutic response against metastatic colorectal cancer
CIHR · 2021 · Co-investigator
86 publications.
F2,6BP restores mitochondrial genome integrity in Huntington's disease.
Chakraborty A, Mandal SM, Mankevich M, Mani RS, Shahabi S, Kodavati M, Sreenivasmurthy SG, Tapryal N, Hamilton DJ, Krishnan B, Hegde ML, Weinfeld M, Ghosh G, Hazra T
Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics.
Mehinrad P, Abdelfattah A, Shafaati T, Emami J, Donnelly J, West FG, Weinfeld M, Lavasanifar A
Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics.
Mehinrad P, Abdelfattah A, Sadat SMA, Shafaati T, Elmenoufy AH, Jay D, West F, Weinfeld M, Lavasanifar A
F2,6BP restores mitochondrial genome integrity in Huntington's Disease.
Chakraborty A, Mandal SM, Mankevich M, Mani RS, Shahabi S, Biswas T, Kodavati M, Sreenivasmurthy SG, Tapryal N, Krishnan B, Hegde ML, Weinfeld M, Ghosh G, Hazra T
The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent.
Ciniero G, Pedro TM, Dumontet C, Elmenoufy AH, West FG, Weinfeld M, Gentile F, Tuszynski JA, Cros-Perrial E, Jordheim LP
PNKP safeguards stalled replication forks from nuclease-dependent degradation during replication stress.
Mashayekhi F, Ganje C, Caron MC, Heyza JR, Gao Y, Zeinali E, Fanta M, Li L, Ali J, Mersaoui SY, Schmidt JC, Godbout R, Masson JY, Weinfeld M, Ismail IH
CDK-dependent phosphorylation regulates PNKP function in DNA replication.
Mashayekhi F, Zeinali E, Ganje C, Fanta M, Li L, Godbout R, Weinfeld M, Ismail IH
Personalized treatment approach for HER2-positive metastatic breast cancer.
Pandey P, Chaudhary R, Tripathi D, Lavudi K, Dua K, Weinfeld M, Lavasanifar A, Rajinikanth PS
Loss of the DNA repair protein, polynucleotide kinase/phosphatase, activates the type 1 interferon response independent of ionizing radiation.
Kate WD, Fanta M, Weinfeld M
Detection of Uracil-Excising DNA Glycosylases in Cancer Cell Samples Using a Three-Dimensional DNAzyme Walker.
Tao J, Zhang H, Weinfeld M, Le XC
Polynucleotide kinase/phosphatase: its role in DNA strand break repair and a potential cancer therapeutic target
Principal investigators: Weinfeld, Michael
Keywords: Dna Repair; Synthetic Lethality; Type 1 Interferon Response
Nano-carriers of novel inhibitors of DNA repair for enhanced therapy in unresectable lung cancer
Principal investigators: Lavasanifar, Afsaneh
Keywords: Cancer; Chemotherapy; Dna Damage; Dna Repair; Drug Delivery; Imaging; Nanotechnology; Radiotherapy
Targeted delivery of novel inhibitors of DNA repair and combination treatments for the modulation of therapeutic response against metastatic colorectal cancer
Principal investigators: Lavasanifar, Afsaneh
Keywords: Cancer Therapy; Chemo Sensitization; Dna Repair; Drug Delivery; Drug Targeting; Immnotherapy; Metastatic Colorectal Cancer; Nanotechnology; Radio Sensitization
Polynucleotide kinase/phosphatase: its role in DNA strand break repair and a potential therapeutic target to enhance radio- and chemotherapy
Principal investigators: Weinfeld, Michael
Keywords: Dna Repair; Synthetic Lethality
Nanodelivery systems for targeted inhibition of DNA repair in the treatment of unresectable lung cancer
Principal investigators: Lavasanifar, Afsaneh
Keywords: Animal Studies; Cell Culture; Chemotherapy; Dna Repair; Drug Development; Drug Targeting; Lung Cancer; Nanotechnology; Pharmaceutical Chemistry; Radiation Therapy
Nano-delivery of novel inhibitors of polynucleotide kinase/phosphatase (PNKP) for tumor targeted sensitization of colorectal cancer to DNA damage.
Principal investigators: Sadat, Sams M
Keywords: Cancer Therapy; Colorectal Cancer; Dna Repair; Drug Delivery System; Drug Resistance; Human Polynucleotide Kinase/Phosphatase (Pnkp); Nanotechnology; Pnkp Inhibitor; Sensitization For Permanent Dna Damage; Targeted Nanoparticle
Chemical genetic screen for cell surface receptors that control cancer stem cell differentiation
Principal investigators: Derda, Ratmir
Keywords: Asymmetric Division; Biomaterials; Cancer Stem Cells; Cell Reprogramming; Cell Surface Receptors; Chemical Genetics; Differentiation; Genetically-Encoded Libraries; Peptides; Phage Display
Polynucleotide kinase: its role in DNA strand break repair and a potential therapeutic target to enhance radio- and chemotherapy
Principal investigators: Weinfeld, Michael
Keywords: Biophysical Approaches; Dna Damage; Dna Repair; Ionizing Radiation; Protein-Protein Interactions; Synthetic Lethality
Mechanisms of arsenic carcinogenesis
Principal investigators: Le, Xiaochun C
Keywords: Arsenic; Carcinogenesis; Dna Damage And Repair; Environmental Health; P53 Protein
Understanding the role of Notch signaling in ovarian cancer stem cells
Principal investigators: Zepeda, Nubia I
Keywords: Cancer Stem Cells; Chemoresistance; Flow Cytometry; Monolayer Culture; Notch Inhibitors; Notch Signalling; Ovarian Cancer; Skov3 Cells; Sphere Culture; Xenograft Model
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Oncology
- Medical Microbiology and Immunology
- Laboratory Medicine and Pathology
- Microbiology and Infectious Diseases
- Chemical and Materials Engineering
- Chemistry
- Biochemistry
- Other
Co-authors at University of Alberta, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Afsaneh Lavasanifar
Faculty
13 shared papers, latest 2026
Richard Fahlman
Faculty
2 shared papers, latest 2021
Edan Foley
Medical Microbiology and Immunology
2 shared papers, latest 2013
Roseline Godbout
Oncology
2 shared papers, latest 2024
Sambasivarao Damaraju
Laboratory Medicine and Pathology
2 shared papers, latest 2021
Frank Wuest
Oncology
1 shared papers, latest 2020
Antoine Dufour
Microbiology and Infectious Diseases
1 shared papers, latest 2021
Nicolas Touret
Biochemistry
1 shared papers, latest 2015
Frederick West
Medical Microbiology and Immunology
1 shared papers, latest 2025
Liang Li
Chemistry
1 shared papers, latest 2005
Xiaoyan Jiang
Terry Fox Laboratory
1 shared papers, latest 2014
Ina Dobrinski
Faculty
1 shared papers, latest 2021
Lynne-Marie Postovit
Oncology
1 shared papers, latest 2019
Hasan Uludag
Chemical and Materials Engineering
1 shared papers, latest 2007
Jean-Yves Masson
Faculty
1 shared papers, latest 2024
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.